MA51916A - Compositions pour le traitement de la dégénérescence maculaire liée à l'âge humide - Google Patents

Compositions pour le traitement de la dégénérescence maculaire liée à l'âge humide

Info

Publication number
MA51916A
MA51916A MA051916A MA51916A MA51916A MA 51916 A MA51916 A MA 51916A MA 051916 A MA051916 A MA 051916A MA 51916 A MA51916 A MA 51916A MA 51916 A MA51916 A MA 51916A
Authority
MA
Morocco
Prior art keywords
compositions
treatment
macular degeneration
related macular
wet age
Prior art date
Application number
MA051916A
Other languages
English (en)
Inventor
Everen Sherri Van
James M Wilson
Stephen Yoo
Original Assignee
Regenxbio Inc
Univ Pennsylvania
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regenxbio Inc, Univ Pennsylvania filed Critical Regenxbio Inc
Publication of MA51916A publication Critical patent/MA51916A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/20—Animal model comprising regulated expression system
    • A01K2217/203—Animal model comprising inducible/conditional expression system, e.g. hormones, tet
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14145—Special targeting system for viral vectors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
MA051916A 2018-02-20 2019-02-19 Compositions pour le traitement de la dégénérescence maculaire liée à l'âge humide MA51916A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862632775P 2018-02-20 2018-02-20
US201862663532P 2018-04-27 2018-04-27

Publications (1)

Publication Number Publication Date
MA51916A true MA51916A (fr) 2021-05-26

Family

ID=67688300

Family Applications (1)

Application Number Title Priority Date Filing Date
MA051916A MA51916A (fr) 2018-02-20 2019-02-19 Compositions pour le traitement de la dégénérescence maculaire liée à l'âge humide

Country Status (10)

Country Link
US (1) US20210093734A1 (fr)
EP (1) EP3755804A4 (fr)
JP (2) JP2021516671A (fr)
KR (1) KR20210022524A (fr)
AU (1) AU2019223963A1 (fr)
CA (1) CA3090293A1 (fr)
IL (1) IL276777A (fr)
MA (1) MA51916A (fr)
SG (1) SG11202007252VA (fr)
WO (1) WO2019164854A1 (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11223668B2 (en) * 2017-01-12 2022-01-11 Telefonaktiebolaget Lm Ericsson (Publ) Anomaly detection of media event sequences
WO2019067540A1 (fr) * 2017-09-27 2019-04-04 Regenxbio Inc. Traitement de maladies oculaires avec un fab anti-vegf à modification post-traductionnelle totalement humain
EA202091509A1 (ru) 2017-12-19 2020-09-22 Акуос, Инк. Aav-опосредованная доставка терапевтических антител во внутреннее ухо
US11360969B2 (en) * 2019-03-20 2022-06-14 Promethium, Inc. Natural language based processing of data stored across heterogeneous data sources
WO2021046245A1 (fr) * 2019-09-04 2021-03-11 University Of Massachusetts Plateforme de vecteur de virus adéno-associé pour l'administration de kh902 (conbercept) et ses utilisations
WO2021174175A1 (fr) * 2020-02-28 2021-09-02 The Trustees Of The University Of Pennsylvania Traitement de bestrophinopathies récessives autosomiques et procédés d'évaluation de celles-ci
WO2021217178A1 (fr) * 2020-04-24 2021-10-28 Siemens Healthcare Diagnostics Inc. Réactifs d'étalonnage et de contrôle de qualité destinés à être utilisés avec des dosages immunologiques pour des anticorps
WO2021255589A1 (fr) * 2020-06-16 2021-12-23 Intas Pharmaceuticals Ltd. Vecteur de virus adéno-associé (vaa) scfab anti-vegf et ses utilisations
WO2021255590A1 (fr) * 2020-06-16 2021-12-23 Intas Pharmaceuticals Ltd. Vecteur de virus adéno-associé (aav) anti-vegf et ses utilisations
WO2022079453A1 (fr) 2020-10-16 2022-04-21 Gyroscope Therapeutics Limited Acide nucléique codant pour une entité anti-vegf et un régulateur de complément négatif et leurs utilisations pour le traitement de la dégénérescence maculaire liée à l'âge
IL303317A (en) * 2020-12-01 2023-07-01 Akouos Inc ANTI-NATURAL ANTIBODY STRUCTURES AND RELATED METHODS FOR THE TREATMENT OF SYMPTOMS ASSOCIATED WITH VESTIBULAR SWANNOMA
MX2023008826A (es) 2021-02-01 2023-09-15 Regenxbio Inc Terapia génica para lipofuscinosis neuronal ceroidea.
WO2023014892A1 (fr) * 2021-08-04 2023-02-09 Alpine Biotherapeutics Corporation Administration intraoculaire durable médiée par des cellules oculaires d'agents thérapeutiques cellulaires pour le traitement de maladies ou de troubles oculaires
CN114181972A (zh) * 2021-11-23 2022-03-15 上海本导基因技术有限公司 适用于难治性血管新生性眼疾病基因治疗的慢病毒载体
TW202342525A (zh) * 2022-02-02 2023-11-01 美商阿科奧斯公司 用於治療前庭神經鞘瘤相關症狀之抗ｖｅｇｆ抗體構築體及相關方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA44873A (fr) * 2016-04-15 2019-03-13 Univ Pennsylvania Composition pour le traitement de la dégénérescence maculaire liée a l'âge exsudative
AU2017250797A1 (en) * 2016-04-15 2018-10-25 Regenxbio Inc. Treatment of ocular diseases with fully-human post-translationally modified anti-VEGF fab

Also Published As

Publication number Publication date
US20210093734A1 (en) 2021-04-01
SG11202007252VA (en) 2020-09-29
IL276777A (en) 2020-10-29
EP3755804A4 (fr) 2021-12-15
AU2019223963A1 (en) 2020-08-13
KR20210022524A (ko) 2021-03-03
JP2024016207A (ja) 2024-02-06
CA3090293A1 (fr) 2019-08-29
JP2021516671A (ja) 2021-07-08
EP3755804A1 (fr) 2020-12-30
WO2019164854A1 (fr) 2019-08-29

Similar Documents

Publication Publication Date Title
MA51916A (fr) Compositions pour le traitement de la dégénérescence maculaire liée à l'âge humide
MA44873A (fr) Composition pour le traitement de la dégénérescence maculaire liée a l'âge exsudative
MA55974A (fr) Composés triaryles pour le traitement de maladies pd-l1
MA51200A (fr) Nouveaux composés et compositions pharmaceutiques associées pour le traitement de maladies
MA44083A (fr) Composés de biarylmonobactame pour le traitement d'infections bactériennes
MA49279A (fr) Compositions d'anticorps optimisées pour le traitement de troubles oculaires
MA45481A (fr) Utilisation d'exosomes pour le traitement de maladies
MA55325A (fr) Composés pour le traitement de maladies pd-l1
MA55629A (fr) Compositions d'anticorps pour le traitement de tumeurs
MA44737A (fr) Compositions pour le traitement de troubles liés à l'hyperkératose
MA47719A (fr) Esketamine pour le traitement de la dépression
MA42953A (fr) Composés et compositions pour le traitement de troubles oculaires
MA51677A (fr) Méthodes de traitement du cancer à l'aide d'anticorps anti-pd-1
MA52631A (fr) Compositions et méthodes pour le traitement de la maladie de parkinson
DK3720433T3 (da) Bis-cholin-tetrathiomolybdat til behandling af wilsons sygdom
MA45552A (fr) Compositions destinées au traitement de l'amylose
MA53873A (fr) Compositions et procédés pour le traitement de la presbytie
IL281773A (en) Eye preparation for the treatment of dry eye disease
MA49576A (fr) Compositions et méthodes pour le traitement d'infections fongiques
MA51672A (fr) Composés destinés au traitement des troubles kinases-dépendants
MA53614A (fr) Protéine pour le traitement de maladies inflammatoires
MA46099A (fr) Composés pour le traitement de maladies associées à un dysfonctionnement mitochondrial
MA52199A (fr) Compositions et procédés de traitement de la dystrophie maculaire
MA54792A (fr) Compositions et méthodes pour le traitement de la maladie de parkinson
MA54522A (fr) Composition pharmaceutique pour le traitement de l'hypertension artérielle pulmonaire